The Doctors Company has completed its $1.3 billion acquisition of ProAssurance Corporation, creating one of the largest medical professional liability insurers in the US with $12 billion in assets and coverage for more than 200,000 healthcare professionals and organizations nationwide. The deal closes at a moment of sustained and intensifying pressure on the US medical malpractice market.
The AMA's April 2026 Policy Research Perspective report confirmed that medical liability premiums rose for the seventh consecutive year in 2025, with 39.9% of premiums increasing - the highest rate since 2005 outside the 2024 peak of 49.8%. Increases were concentrated in Pennsylvania, where 92.2% of reported premiums rose, and New York, where 95.7% increased. Underlying the premium trajectory is a severity crisis: median awards for major malpractice cases more than doubled in 2025, verdicts above $10 million have more than doubled since 2015, and S&P Global found that physician-related payments of $500,000 or more accounted for 36.5% of all payments in 2024 - a new high. The Doctors Company itself has described the current environment as "an era marked by nuclear malpractice verdicts." Its own commissioned research estimated that economic and social inflation added $4 billion in insured losses and expenses to the physician-focused segment over the decade ending in 2024.
It is in that market that The Doctors Company, led by chairman and CEO Richard Anderson (pictured) - already the second-largest writer of medical professional liability insurance in the US, according to AM Best - has acquired ProAssurance at a 60% premium to its pre-announcement share price.
The Napa, California-based insurer acquired all outstanding shares of ProAssurance for $25 per share in cash. ProAssurance's common stock has been delisted from the New York Stock Exchange and deregistered with the SEC. ProAssurance will function as a wholly owned subsidiary of The Doctors Company while a review is conducted to identify the optimal operating structure.
The deal was first announced on March 19, 2025. The FTC granted early termination of the Hart-Scott-Rodino antitrust waiting period on July 2, 2025. ProAssurance shareholders voted to approve the transaction that same month, with state-level insurance regulatory approvals in California, Pennsylvania and Texas representing the final conditions to closing.
AM Best confirmed at the time of the deal announcement that it did not expect the transaction to affect the A (Excellent) financial strength rating of either company - a finding that matters directly to the combined entity's policyholders, for whom continuity of claims-paying ability is the central concern in any ownership change.
ProAssurance's specialty lines footprint extends well beyond traditional physician liability. Its expertise in products liability for medical technology and life sciences companies, alongside its workers' compensation book, gives the enlarged group a broader platform from which to serve healthcare organizations of all sizes - from individual clinicians to academic medical systems. The combined organization will provide coverage across medical professional liability, medical technology and life sciences products liability, and workers' compensation insurance.
The 60% acquisition premium reflects ProAssurance's strategic value in a concentrated market where the largest national writers carry significant influence over the rate environment. In a market defined by rising severity, nuclear verdicts and seven consecutive years of premium increases, the case for combining two complementary specialist franchises under a single capital base is straightforward: the cost of defending and resolving claims at scale favors carriers with deep reserves, broad reinsurance relationships and the claims expertise to contest large verdicts rather than settle them.
